Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers

被引:51
|
作者
Aparicio, Hugo J. [1 ,2 ]
Carr, Brendan G. [5 ]
Kasner, Scott E. [2 ]
Kallan, Michael J. [3 ]
Albright, Karen C. [6 ,7 ,8 ]
Kleindorfer, Dawn O. [9 ]
Mullen, Michael T. [2 ,4 ]
机构
[1] Boston Univ, Dept Neurol, Boston, MA 02215 USA
[2] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[5] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA
[6] Univ Alabama Birmingham, Hlth Serv & Outcomes Res Ctr Outcome & Effectiven, Birmingham, AL USA
[7] Univ Alabama Birmingham, Ctr Excellence Comparat Effectiveness Res Elimina, Minor Hlth & Hlth Dispar Res Ctr, Birmingham, AL USA
[8] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA
[9] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
health disparities; health policy; stroke; stroke care; thrombolysis; ACUTE ISCHEMIC-STROKE; CERTIFIED PRIMARY STROKE; AMERICAN-HEART-ASSOCIATION; MEDICAL-SERVICES USE; ETHNIC DISPARITIES; TEMPORAL TRENDS; UNITED-STATES; RISK-FACTORS; OUTCOMES; EMERGENCY;
D O I
10.1161/JAHA.115.001877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Primary stroke centers (PSCs) utilize more recombinant tissue plasminogen activator (rt-PA) than non-PSCs. The impact of PSCs on racial disparities in rt-PA use is unknown. Methods and Results-We used data from the Nationwide Inpatient Sample from 2004 to 2010, limited to states that publicly reported hospital identity and race. Hospitals certified as PSCs by The Joint Commission were identified. Adults with a diagnosis of ischemic stroke were analyzed. Rt-PA use was defined by the International Classification of Diseases, 9th Revision procedure code 99.10. Discharges (304 152 patients) from 26 states met eligibility criteria, and of these 71.5% were white, 15.0% black, 7.9% Hispanic, and 5.6% other. Overall, 24.7% of white, 27.4% of black, 16.2% of Hispanic, and 29.8% of other patients presented to PSCs. A higher proportion received rt-PA at PSCs than non-PSCs in all race/ethnic groups (white 7.6% versus 2.6%, black 4.8% versus 2.0%, Hispanic 7.1% versus 2.4%, other 7.2% versus 2.5%, all P<0.001). In a multivariable model adjusting for year, age, sex, insurance, medical comorbidities, a diagnosis-related group-based mortality risk indicator, ZIP code median income, and hospital characteristics, blacks were less likely to receive rt-PA than whites at non-PSCs (odds ratio=0.58, 95% CI 0.50 to 0.67) and PSCs (odds ratio=0.63, 95% CI 0.54 to 0.74) and Hispanics were less likely than whites to receive rt-PA at PSCs (odds ratio=0.77, 95% CI: 0.63 to 0.95). In the fully adjusted model, interaction between race and presentation to a PSC for likelihood of receiving rt-PA did not reach significance (P=0.98). Conclusions-Racial disparities in intravenous rt-PA use were not reduced by presentation to PSCs. Black patients were less likely to receive thrombolytic treatment than white patients at both non-PSCs and PSCs. Hispanic patients were less likely to be seen at PSCs relative to white patients and were less likely to receive intravenous rt-PA in the fully adjusted model.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] CIRCADIAN VARIATION OF EFFICACY OF INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR IN PATIENTS WITH ACUTE ISCHEMIC STROKE
    Lee, S.
    Kim, J. H.
    INTERNATIONAL JOURNAL OF STROKE, 2018, 13 : 116 - 116
  • [42] INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE CAROTID-ARTERY TERRITORY STROKE
    MORI, E
    YONEDA, Y
    TABUCHI, M
    YOSHIDA, T
    OHKAWA, S
    OHSUMI, Y
    KITANO, K
    TSUTSUMI, A
    YAMADORI, A
    NEUROLOGY, 1992, 42 (05) : 976 - 982
  • [43] A Myocardial Infarction During Intravenous Recombinant Tissue Plasminogen Activator Infusion for Evolving Ischemic Stroke
    Fitzek, Sabine
    Fitzek, Clemens
    NEUROLOGIST, 2015, 20 (03) : 46 - 47
  • [44] Borderline Elevation of International Normalized Ratio and Use of Intravenous Recombinant Tissue Plasminogen Activator
    Aggarwal, Harsh R.
    Hassan, Ameer E.
    Rodriguez, Gustavo J.
    Suri, M. Fareed K.
    Lakshminarayan, Kamakshi
    Taylor, Robert A.
    Ezzeddine, Mustapha A.
    Qureshi, Adnan I.
    NEUROLOGY, 2010, 74 (09) : A511 - A511
  • [45] Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers
    Imbarrato, Gregory
    Bentley, Joshua
    Gordhan, Ajeet
    JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE, 2018, 9 (02) : 240 - 244
  • [46] Safety of intravenous recombinant tissue plasminogen activator in recent trauma
    Zabeen Mahuwala
    Archana Hinduja
    Acta Neurologica Belgica, 2014, 114 : 163 - 164
  • [47] Safety of intravenous recombinant tissue plasminogen activator in recent trauma
    Mahuwala, Zabeen
    Hinduja, Archana
    ACTA NEUROLOGICA BELGICA, 2014, 114 (02) : 163 - 164
  • [48] Stroke Patients Transported To A Primary Stroke Center More Likely To Receive Intravenous Tissue Plasminogen Activator
    Sen, Souvik
    Hawsey, Kelly
    Burdine, Joselyn
    Kowalczyk, Hannah E.
    Sumner, Roxanne
    Finney, Chris
    Brown, Jordan
    Heidari, Khosrow
    STROKE, 2013, 44 (02)
  • [49] Does Mild Deficit for Patients with Stroke Justify the Use of Intravenous Tissue Plasminogen Activator?
    Hassan, Ameer E.
    Zacharatos, Haralabos
    Hassanzadeh, Bahareh
    El-Gengaihy, Ahmed
    AlKawi, Ammar
    Shhadeh, Akram
    Kirmani, Jawad F.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2010, 19 (02): : 116 - 120
  • [50] Does mild deficit for stroke patients justify the use of intravenous tissue plasminogen activator?
    Hassan, Ameer E.
    AlKawi, Ammar
    Khan, Hafiz M.
    Malik, Rehan A.
    Shhadeh, Akram
    Kirmani, Jawad F.
    STROKE, 2008, 39 (02) : 726 - 726